3 results
The primary objective of this PMCF study is to confirm device survivorship of the GLOBAL ICON stemless humeral component at 24 months post-operative.The secondary objectives include the evaluation of clinical performance, radiographic performance…
In this study, we look at how safe the new medicinal product XMT-1536 is for the treatment of ovarian cancer and how well it works. We compare the effect of XMT-1536 with the effect of a placebo. A placebo is a product without the active ingredient…
Phase 1 - AMG 701 dose-exploration as monotherapyPrimary Objectives:• Evaluate the safety and tolerability of AMG 701 in subjects with relapsed/refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) and/or recommended phase…